Indefinite Delivery Contract SPE2DR25D9226

The federal contract IDV award SPE2DR25D9226 is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $499,999,999, covers a comprehensive range of pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the recurring medical supply needs of military healthcare facilities and veterans' medical centers nationwide.

The original solicitation, planned for release in March 2024, is for the DLA Troop Support Medical Supply Chain's Pharmaceutical Prime Vendor Global Program Generation V contracts. The contracts will have a 30-month base period and three 30-month option periods, with an estimated total value of $30.3 billion. The solicitation aims to establish multiple primary supplier awards for separate regions (North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet) as well as a single backup supplier award, with the intention of diversifying the Department of Defense's pharmaceutical supply chain to increase resiliency during contingencies or natural disasters. The contract will be awarded on a lowest price technically acceptable basis, with the option to utilize a reverse auction process to determine the final distribution fees.